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variant in CALHM1 and AD risk (p values 
ranging from 0.15 to 0.84). Stratification by 
age of AD onset (using 65 years as cutoff) 
or APOE ε4-genotype did not apprecia-
bly change these results (data not shown; 
stratified analyses were not possible in 
the GWAS samples as no onset age or 
APOE ε4 data were supplied). Effect size 
estimates indicated insignificant ORs 
that were opposite in direction to those 
reported by Dreses-Werringloer et al. 
(2008) in six of the eight samples (see Fig-
ure S1). Accordingly, summary ORs calcu-
lated across the newly genotyped samples 
in our study (labeled “This study” in Figure 
S1) were insignificant (OR = 0.94 [95% CI: 
0.83–1.07], p = 0.4) and tended toward 
null when combined with the published 
GWAS genotype data (“All follow-up”; OR 
= 0.99 [95% CI: 0.91–1.09], p = 0.9). Upon 
combining these data with the results of 
the original study (“All studies”), that is, 
generating a meta-analysis on all ~11,700 
currently available subjects, the overall 
summary OR became insignificant as well 
(OR = 1.13 [95% CI: 0.99–1.27], p = 0.06). 
Using rs1555823 (instead of rs2986030) as 
proxy for the rs2986017 (Pro86Leu) variant 
in the GWAS samples revealed even less 
pronounced and less significant overall 
effects (data not shown).
Thus, we have independently assessed 
the potential association between AD risk 
and the rs2986017 (Pro86Leu) variant in the 
CALHM1 gene in a large number of inde-
pendent datasets, including AD families 
in which the original chromosome 10q24 
linkage signal was identified (Bertram et 
al., 2000). Despite good to excellent power 
to detect genetic effect sizes on the order 
described by Dreses-Werringloer et al. 
(2008), no association between CALHM1 
and AD was observed, either in the indi-
vidual samples or in the combined analy-
ses of more than 8100 subjects. Based 
on these negative data, it is doubtful that 
CALHM1 represents more than a minor 
genetic determinant of AD risk.
Supplemental Data
Supplemental Data include two tables and one figure 
and can be found with this article online at http://www.
cell.com/supplemental/S0092-8674(08)01505-5.
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(2007). Neuron 54, 713–720.We recently reported the association of the 
CALHM1 gene with late-onset Alzheimer’s 
disease (LOAD) risk in four independent 
populations of more than 3000 partici-
pants (Dreses-Werringloer et al., 2008). 
We showed that the rare allele of the non-
synonymous SNP rs2986017 in CALHM1 
increases LOAD risk by about 40% (p = 
2 × 10−10). Importantly, we also demon-
strated the functional significance of the 
CALHM1 rs2986017 SNP by showing that 
the corresponding Pro86Leu polymor-
phism increased levels of the pathogenic 
peptide, Aβ (Dreses-Werringloer et al., 
2008). In their Correspondence, Bertram 
et al. independently assess the associa-
Response 
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report an inability to replicate the associa-
tion in more than 5000 individuals. Here, 
we comment on several important meth-
odological points in the study of Bertram 
et al., and we present new evidence that 
supports the association of CALHM1 with 
both LOAD risk and age of AD onset.
Family-Based Association Studies
The main contribution of the Bertram et al. 
study lies in the analysis of the CALHM1 
rs2986017 SNP on LOAD risk in four inde-
pendent family-based populations. The 
authors observed no significant genetic 
association. They combined these family-
based studies with case-control studies in 
a meta-analysis. However, the authors did 
not present a test of heterogeneity, which 
is a crucial prerequisite for a meta-anal-
ysis (Epstein et al., 2005). Furthermore, 
a meta-analysis combining family-based 
studies and case-control studies calls for 
specific methods (as described in Curtin 
et al., 2007; Epstein et al., 2005; Nicode-
mus, 2008), but none of these approaches 
seem to have been used by Bertram et 
al. For these reasons, the interpretation 
of their data is hampered by the inappro-
priate combination of methodologically 
distinct studies. The family-based studies 
should not have been combined with the 
case-control studies.
Minor Allele Frequency Estimation
We note that the minor allele frequency 
(MAF) estimations of the CALHM1 
rs2986017 SNP reported by Bertram et 
al. significantly differ from our previous 
estimations. Considering only controls 
in the Bertram et al. analysis, in family-
based studies and in studies from Fin-
land and Sweden, which measured 
directly the CALHM1 rs2986017 SNP, the 
MAF estimations reported by Bertram et 
al. averaged 0.278 (±0.0138 SEM). In the 
populations that we genotyped, the MAF 
estimations averaged 0.226 (±0.0151 
SEM). This difference is statistically sig-
nificant (two-tailed t test, p value = 0.027, 
see Figure S1A available online). Interest-
ingly, in the Swedish cohort, where the 
odds ratio (OR) follows a trend consis-
tent with our observations (see Table S2 
of the Bertram et al. Correspondence), a 
MAF estimation of 0.20 was found, con-
sistent with the MAF variance observed 
across populations in our previous study 
(t test 0.20 versus MAF in our study, p = 
0.17, see Figure S1A). When considering 
all studies, the MAF estimations for the 
CALHM1 rs2986017 SNP significantly 
associate with the ORs (see Figure S1B, 
which compares cohorts with OR ≥ 1.1 
and other cohorts, two-tailed t test, p 
value = 0.0002). Although MAF variations 
are known to correlate with geography 
(e.g., Novembre et al., 2008) and ApoE 
MAFs have been shown to vary from 
Southern to Northern Europe (Lucotte et 
al., 1997), the comparison between the 
MAFs measured in Italy (0.23), Sweden 
(0.20), and Finland (0.31) suggest that 
geography alone cannot account for the MAF variations observed in the Bertram 
et al. study. These MAF variations in con-
trol populations are unexplained at this 
point but clearly represent a problem 
that hampers the application of meta-
analysis methodologies in the Bertram 
et al. study (Epstein et al., 2005).
Genome-Wide Association Studies
In their Correspondence, Bertram et al. 
report the analysis of two publicly avail-
able genome-wide association studies 
(GWAS) datasets (Li et al., 2008; Rei-
man et al., 2007). Because the CALHM1 
rs2986017 SNP was not genotyped in 
these GWAS, two other SNPs (rs2986030, 
rs1555823), used as surrogate markers, 
were analyzed. This approach is not a 
replication per se and can offer at best 
only an approximation of the strength of 
an association. Bertram and colleagues 
report the following linkage disequilibrium 
values between the CALHM1 rs2986017 
SNP and the two markers: r2 (rs2986030, 
rs2986017) = 0.71 and r2 (rs1555823, 
rs2986017) = 0.64. The HapMap consor-
tium recommends using a SNP r2 cutoff 
of 0.8 to select SNP proxies. By perform-
ing our own linkage disequilibrium analy-
sis in 756 controls between the CALHM1 
rs2986017 SNP and a subset of other 
SNPs, we determined that rs2986018 is a 
good marker for the CALHM1 rs2986017 
SNP, with an r2 of 0.86 (NYCP cohort, n 
= 756, age = 46.3 ± 9.5 years, 81% male; 
see Figure S1C) (Mitchell et al., 2004). 
The HapMap consortium considers that 
a SNP is a good marker for another SNP 
if the r2 of the two SNPs is larger than 
0.8 (the SNPs are said to tag each other, 
as the measurement of one informs the 
measurement of the other). According 
to HapMap data, rs2986018 is an inde-
pendent SNP not tagging other SNPs, 
whereas rs2986030 belongs to a set of 
tag SNPs with r2 > 0.8, which does not 
include the CALHM1 rs2986017 SNP. 
Therefore, rs2986030 and rs1555823 
used in the Bertram et al. study do not 
represent appropriate surrogate markers 
for the CALHM1 rs2986017 SNP, which 
our study measured directly (Dreses-
Werringloer et al., 2008).
Both the number of SNPs analyzed 
and the number of samples in a cohort 
can determine the probability of detect-
ing an association using a local replica-
tion strategy (Clarke et al., 2007). Thus, Cell 135, Dwe re-analyzed and combined the 
GWAS data in order to consider SNPs 
in the CALHM1 region that are shared 
by the two platforms. This strategy 
reduces the number of SNPs tested and 
increases the number of samples avail-
able, thereby increasing the power to 
detect an association. Four SNPs were 
shared by the platforms in the region of 
CALHM1: rs7831, rs755577, rs2986030, 
and rs1555823. Two of these four SNPs 
indicate a weak, but significant, asso-
ciation with disease risk (rs7831: OR = 
1.15, CI 95% [1.03–1.29], p = 0.01 and 
rs755577: OR = 1.14, CI 95% [1.01–1.28], 
p = 0.03). Furthermore, Li et al. (2008) 
have reported that rs2986030 appears 
to modulate the age of AD onset 
(recessive model, HR = 1.45, CI 95% 
[1.05–2.08], p = 0.02), an observation 
in agreement with our finding for the 
CALHM1 rs2986017 SNP. Therefore, the 
use of marker analysis in the available 
GWAS datasets cannot exclude the pos-
sibility that CALHM1 is associated with 
LOAD. Moreover, given that the Bertram 
et al. results were obtained by a proxy 
approach, they should not be combined 
in a meta-analysis that includes studies 
for which the CALHM1 rs2986017 SNP 
was measured directly.
Conclusion
The Bertram et al. study is a negative 
replication of the association between 
CALHM1 and LOAD risk. However, for 
the reasons described here, we believe 
that the results from the different cohorts 
analyzed in the Bertram et al. study have 
been improperly aggregated and that 
the GWAS data must be re-analyzed for 
local association following established 
methodologies, as we have pointed out. 
However, the replication study does 
raise interesting questions related to the 
lack of association in family-based stud-
ies and to the heterogeneity of CALHM1 
rs2986017 SNP frequency among dif-
ferent control groups. Nevertheless, it is 
our opinion that the Bertram et al. results 
do not allow a firm conclusion that there 
is no association between CALHM1 
and LOAD risk in the populations that 
Bertram et al. tested. In line with these 
observations, we have provided addi-
tional data to further support the notion 
that CALHM1 modulates both disease 
risk and age of AD onset.ecember 12, 2008 ©2008 Elsevier Inc. 995
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